Alain Anne-Volny

Brussels, BRU, Belgium

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

Including people with HIV in non-HIV clinical trials.

Including people with HIV in non-HIV clinical trials.

Journal: British journal of nursing (Mark Allen Publishing)

Published: March 10, 2025

Establishing shared definitions of virological failure and discontinuation for long-acting injectable cabotegravir and rilpivirine therapy (the CONSENSUS-LAI Study): an international survey and Delphi process.

Establishing shared definitions of virological failure and discontinuation for long-acting injectable cabotegravir and rilpivirine therapy (the CONSENSUS-LAI Study): an international survey and Delphi process.

Journal: The lancet. HIV

Published: January 08, 2025

Risk of tuberculosis after initiation of antiretroviral therapy among persons with HIV in Europe.

Risk of tuberculosis after initiation of antiretroviral therapy among persons with HIV in Europe.

Journal: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases

Published: May 07, 2024

Changes in bodyweight after initiating antiretroviral therapy close to HIV-1 seroconversion: an international cohort collaboration.

Changes in bodyweight after initiating antiretroviral therapy close to HIV-1 seroconversion: an international cohort collaboration.

Journal: The lancet. HIV

Published: April 15, 2024

HIV prevention and missed opportunities among people with recently acquired HIV infection: Α protocol for a systematic review.

HIV prevention and missed opportunities among people with recently acquired HIV infection: Α protocol for a systematic review.

Journal: PloS one

Published: November 29, 2023

A systematic review of qualitative research on recently acquired HIV.

A systematic review of qualitative research on recently acquired HIV.

Journal: AIDS (London, England)

Published: August 31, 2023

CASCADE protocol: exploring current viral and host characteristics, measuring clinical and patient-reported outcomes, and understanding the lived experiences and needs of individuals with recently acquired HIV infection through a multicentre mixed-methods observational study in Europe and Canada.

CASCADE protocol: exploring current viral and host characteristics, measuring clinical and patient-reported outcomes, and understanding the lived experiences and needs of individuals with recently acquired HIV infection through a multicentre mixed-methods observational study in Europe and Canada.

Journal: BMJ open

Published: May 11, 2023

Plasma Human Immunodeficiency Virus 1 RNA and CD4+ T-Cell Counts Are Determinants of Virological Nonsuppression Outcomes With Initial Integrase Inhibitor-Based Regimens: A Prospective RESPOND Cohort Study.

Plasma Human Immunodeficiency Virus 1 RNA and CD4+ T-Cell Counts Are Determinants of Virological Nonsuppression Outcomes With Initial Integrase Inhibitor-Based Regimens: A Prospective RESPOND Cohort Study.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: December 17, 2022

Incidence of hypertension in people with HIV who are treated with integrase inhibitors versus other antiretroviral regimens in the RESPOND cohort consortium.

Incidence of hypertension in people with HIV who are treated with integrase inhibitors versus other antiretroviral regimens in the RESPOND cohort consortium.

Journal: HIV medicine

Published: December 06, 2021

Clinical Outcomes of 2-Drug Regimens vs 3-Drug Regimens in Antiretroviral Treatment-Experienced People Living With Human Immunodeficiency Virus.

Clinical Outcomes of 2-Drug Regimens vs 3-Drug Regimens in Antiretroviral Treatment-Experienced People Living With Human Immunodeficiency Virus.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: September 18, 2020

Virologic and immunologic outcomes of treatment with integrase inhibitors in a real-world setting: The RESPOND cohort consortium.

Virologic and immunologic outcomes of treatment with integrase inhibitors in a real-world setting: The RESPOND cohort consortium.

Journal: PloS one

Published: March 05, 2020

Patient-Reported Outcomes in First-Line Antiretroviral Therapy: Results From NEAT001/ANRS143 Trial Comparing Darunavir/Ritonavir in Combination With Tenofovir/Emtricitabine or Raltegravir.

Patient-Reported Outcomes in First-Line Antiretroviral Therapy: Results From NEAT001/ANRS143 Trial Comparing Darunavir/Ritonavir in Combination With Tenofovir/Emtricitabine or Raltegravir.

Journal: Journal of acquired immune deficiency syndromes (1999)

Published: September 21, 2018

Showing 1-12 of 20

Last Updated: 09/26/2026